S
ince 1952 when the first cases of allergic bronchopulmonary aspergillosis (ABPA) were diagnosed in England, there has been increased recognition of this disease entity.' In 1968, the year that the first case ofABPA was reported in the United States, an English study found that up to 20 percent ofasthmatic patients hospitalized with chronic pulmonary disability had ABPA.* Since 1968, many adult and pediatric cases have been r e p~r t e d .~ Growing awareness of ABPA, definition of criteria for establishing the diagnosis, and understanding the natural history of this chronic pulmonary disease are responsible for the increased number of reported cases.
ABPA, treated with high dose corticosteroids, presents a difficult problem in clinical management. ~i a gnostic criteria associated with the disease are as follows: (1) asthma; (2) blood eosinophilia (>l,OOO/cu mm); (3) immediate skin reactivity to Aspergillus fumigatus (Af) antigen; ( 4 ) precipitating antibodies against the antigen; (5) elevated serum IgE concentration (>1,000 nglml); (6) history of pulmonary infiltrates; (7) with peribronchial thickening seen on end as ring shadows or in tangent as parallel-line shadows.
As more cases of ABPA have been recognized, certain clinicoroentgenologic patterns have emerged. The observed patterns have recently been organized into a clinical staging system. This staging system aids in management of this patient group that is ordinarily difficult to treat.3 The radiologist must be aware of this disease entity and its roentgenographic manifestations, both minimal and severe. Further, knowledge of response to therapy and the clinical staging of this disease enables the radiologist to play a more active role in the care of these patients. On the basis of clinical, laboratory, and roentgenographic findings, five stages of the disease have been established: (I) acute, (11) remission, (111) exacerbation, (IV) corticosteroid-dependent asthma, and (V) pulmonary fibrosis ( Table I) ."
Because of the difficulty in establishing the diagnosis of ABPA befbre significant bronchiectasis has staging, and therapy, some patients presenting in stage 
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Atypical mycobacterial infection with dissemination following bronchogram at outside institution I will progress to stages 111, IV, and V (Fig 1) . Appropriate corticosteroid therapy can often achieve episodic remission. Long-term effectiveness of this therapeutic modality in either retarding or halting the progressive destriction of pulmonary parenchyma has yet to be established ~learly.~ Between February 1967 and the present, 62 patients with proven ABPA were evaluated at our institution. These patients were nearly evenly divided between males and females. Their ages varied from five years of age to 66 years. All of these patients were evaluated with appropriate roentgenographic and immunologic tests.
The chest roentgenogram and bronchography or tomography were utilized to demonstrate ABPA findings. In selected oatients. a -questionably abnormal roentgenogram led to bronchography in the past. Bronchographic evaluation was replaced by tomography after several patients experienced adverse effects to the bronchographic procedure.
While a large number of immunologic tests are used to detect sensitivity to Aspergillus fumigatus and ABPA, serum IgE levels and precipitating antibodies to A fumigatus are most useful. These tests are performed on all patients at presentation. Following diagnosis, monthly IgE levels are obtained.
Additionally, the baseline level of blood eosinophilia may be determined. Pulmonary function testing (PFT) is performed during the course of their disease, but since PFTs were found to contribute little to clinical management, they are not required in the management protocol.
The protocol for following patients with ABPA advocated by the Allergy Service at our institution calls for chest roentgenograms every three months during the first year following diagnosis, and yearly thereafter. In addition, with any doubling of IgE levels, a chest x-ray film is obtained to exclude an infiltrate occurring during any exacerbation. To determine the role of roentgenographic studies in initial staging and long-term management of patients with ABPA, we reviewed the diagnostic examinations and clinical records of 24 of the 62 patients who have been actively followed at our institution from 1972 to the present. Patients followed at other institutions, lost to follow-up, or deceased have been excluded. 
Staging of Allergic Bronchoscopy Aspergillosis (Mendelson et el)
Of the 24 patients in this series (Table 2) , the largest group, 16, presented with stage I, acute disease. Two patients were classified as stage 11, remission phase, upon presentation, and six patients were in stage IV, corticosteroid-dependent ABPA. The stage I patients achieved remission, with three of the 16 sustaining remission and remaining in stage II. The other 13 patients presenting in stage I progressed to more advanced stages with two classified as stage 111, four in stages I11 to IV, and five in stage IV. Two patients presenting in the first stage developed pulmonary fibrosis (stage V).
Six patients had corticosteroid-dependent asthma (stage IV) when their management began. Two of these patients progressed to stage V, while in four, ABPA was controlled with high dose corticosteroid therapy.
The length of stay in a particular stage varied with the individual patient, as did progression of ABPA. Neither the time course nor advancement of the disease followed a predictable pattern in those patients followed for up to 11 years. The necessity for high dose corticosteroid therapy to control ABPA flares was not a prognostic indicator for development of pulmonary fibrosis. Predisposing factors for development of pulmonary fibrosis within this patient population are not as yet known.
From our review of the sequential examinations of patients with ABPA, we have observed the following roentgenographic changes: proximal bronchiectasis, perhaps the most important finding, tramline and linear shadows, and ring shadows are permanent manifestations. Mucoid impactions and infiltrates ap- pear transiently and do resolve (Fig 1 through 3) . In stages I through IV, and possibly V, the presence of mucoid impactions and infiltrates is evidence for active disease requiring treatment in patients whose chest roentgenograms and/or tomograms exhibit proximal bronchiectasis, the roentgenographic sign of ABPA (Fig 3 through 7) .
The following trends were observed: stage I patients with plain film findings of ABPA responded to therapy by clearing of the migratory infiltrates and areas of mucoid impaction (Fig 1 through 3) . While predominance of upper lobe involvement is clear, the lower lobes are not infrequently affected. The residua of mucoid impactions frequently remain in the lungs manifested by parallel and tramline shadows, as well as ring shadows. These are indicative of bronchiectasis (Fig 6) .
In stage 11, since none of the active manifestations is present (ie, mucoid impaction, tooth paste shadows, etc), the residual changes may be extremely subtle, requiring either tomography or bronchography to establish their presence. Classification of patients in stage I1 by PA roentgenograms obviates the necessity for further roentgenographic evaluation since presence of ABPA has already been established.
In stage 111, (recurrent exacerbation), new infiltrates frequently develop. In a few patients, in addition to areas of new infiltrate, new areas of mucoid impaction and impaction of previously damaged bronchi may be seen. As in stage I, the infiltrates predominate in the upper lung fields and are frequently more central than pneumonias unassociated with eosinophilia. The majority of patients in stage I11 will soon progress to stage IV, although some patients may return to the second stage. No certain prognostic indicators for progression or regression of the disease process have been identified.
In stage IV, corticosteroid-dependent ABPA, the findings are indistinguishable roentgenographically from those of stage I1 patients. Clinically, these patients require corticosteroid treatment for control of asthma. The dose of corticosteroid necessary for control of asthma may be less than that needed to prevent new roentgenographic infiltrates from ABPA.
Stage V is clinically present when there is extensive fibrotic change and irreversible obstructive lung disease based on pulmonary function testing. Neither pulmonary lesions (fibrotic changes) of PFTs are reversed with high dose steroid therapy, although corticosteroids are required for ABPA flaresg No consistent roentgenographic trends are observed in every case.
Because of variability in duration of ABPA prior to treatment, there is no precise roentgenographic correlation with each ofthe clinical stages. In those stage I patients in whom the diagnosis of ABPA is established early and the treatment effective, only the most minimal changes of ABPA may be identifiable. In patients diagnosed only after unrecognized but repeated bouts of untreated ABPA more extensive pulmonary changes are found.
The presence of infiltrates on chest roentgenograms correlates with acute and recurrent exacerbations of ABPA (stages I and 111). The presence of fibrotic changes on roentgenograms which are present in stage V indicates that irreversible pulmonary damage has occurred but does not correlate well with extent of PFT abnormalities.
While roentgenographic severity does not reflect the clinical stage of ABPA predictably, roentgenographic findings are quite useful in establishing a baseline for each individual patient and in following the patient's response to treatment. Further, when exacerbations occur, as evidenced by clinical symptoms and evaluation of serum IgE, confirmatory roentgenographic findings, such as mucoid impactions and infiltrates, reflect the active disease process.
ABPA is a disease with protracted course. The affected patient population is comprised of asthmatics, and ABPA flares may resemble attacks of uncomplicated asthma. ABPA, however, may cause permanent pulmonary changes (ie, bronchiectasis and fibrosis). While the clinical management of ABPA is difficult and progressive disease is common, we believe that the opportunity for early diagnosis and treatment is important to prevent irreversible pulmonary destruction."' Clinicoroentgeographic staging is therefore helpful in the therapeutic management of these patients.
Roentgenographic findings of ABPA seen acutely in stages I, 111, and IV include not only proximal bronchiectasis, the sine qua non of the diagnosis in absence of cystic fibrosis, but also mucoid impaction and pulmonary infiltrates, often in an upper lobe and central distribution. Stage V patients exhibit pulmonary fibrosis upon which the acute changes may also be superimposed.
While there is no diagnostic roentgenographic finding to define a particular stage, there are two major roentgenographic contributions to managing these ABPA patients: first, to establish the diagnosis initially by demonstrating proximal bronchiectasis on plain film, tomography, or bronchography; and, second, to provide a baseline for each individual patient against which to monitor remissions and progressive changes. 
